Loading
Latest filing published 14 Nov 2024 for Coya Therapeutics, Inc., €12k.
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
David S. Snyder is a declared insider at 2 companies; the most frequent names are Coya Therapeutics, Inc. and Exicure, Inc. In total, 3 filings cover trades dated from 12 March 2020 to 14 November 2024.
No open-market sale appears; the market trades are 3 purchases worth €35k. The totals exclude 1 filing filed without an amount. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. So far in 2024, the count stands at 1 purchase and no sales.
Of 3 purchases, 2 formed part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.
On 14 November 2024 came the latest disclosure, an open-market purchase for €12k in Coya Therapeutics, Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations